Completed PHASE4 INTERVENTIONAL NCT00224315

Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial

Sponsor: Central Institute of Mental Health, Mannheim

Conditions Schizophrenia, Schizoaffective Disorder

Updated 5 times since 2017 Last updated: Jun 2, 2008 Started: Nov 30, 2003 Completion: Sep 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00224315, this PHASE4 trial focuses on Schizophrenia, Schizoaffective Disorder and remains completed. Sponsored by Central Institute of Mental Health, Mannheim, it has been updated 5 times since 2003, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Central Institute of Mental Health, Mannheim

Data source: Central Institute of Mental Health, Mannheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mannheim, Germany